Results 71 to 80 of about 13,529 (168)

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential

Translational Oncology, 2019
Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy.
J. Stalinska, E. Zimolag, NA. Pianovich, A. Zapata, A. Lassak, M. Rak, M. Dean, D. Ucar-Bilyeu, D. Wyczechowska, F. Culicchia, L. Marrero, L. Del Valle, J. Sarkaria, F. Peruzzi, BS Jursic, K. Reiss   +15 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9809-9818, November 2026.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]

Journal of Lipid Research, 2010
Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals.
Mary K. Wojczynski, Guimin Gao, Ingrid Borecki, Paul N. Hopkins, Laurence Parnell, Chao-Qiang Lai, Jose M. Ordovas, B. Hong Chung, Donna K. Arnett   +8 more
doaj   +1 more source

Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Hypertriglyceridemia (HTG) arises from the interplay between genetic susceptibility and secondary or precipitating factors, leading to dysregulated triglyceride‐rich lipoprotein (TRL) metabolism. Increased TRL production and impaired clearance promote distinct risk phenotypes: accumulation of apolipoprotein B(apoB)‐containing TRL remnants contributes ...
Shanshan Qi, Weiwei Chen, Kunhao Chen, Song Yang, Sibo Wang, Tongtian Ni, Dan Xu, Enqiang Mao, Erzhen Chen, Ying Chen   +9 more
wiley   +1 more source

Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway

Acta Pharmaceutica Sinica B
Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely prescribed for hyperlipidemia management. Recent studies also showed that it has therapeutic potential in various liver diseases.
Shicheng Fan, Yue Gao, Pengfei Zhao, Guomin Xie, Yanying Zhou, Xiao Yang, Xuan Li, Shuaishuai Zhang, Frank J. Gonzalez, Aijuan Qu, Min Huang, Huichang Bi   +11 more
doaj   +1 more source

A Combination Strategy for MASH: ACLY Inhibition Paired With PPARα Agonism

iNew Medicine, EarlyView.
Dongdong Wang
wiley   +1 more source

Network Biology: Current Status, Applications, Challenges, and Future Prospects

MedComm, Volume 7, Issue 10, October 2026.
Network biology integrates molecular interaction, intracellular regulatory, single‐cell and multicellular, microbial and host–microbiome, disease, and interorgan networks across biological scales. Perturbation models, multiomics, spatial profiling, computational inference, mechanistic modeling, and AI enable dynamic network reconstruction and causal ...
Xinmeng Li, Laizhong Zhang, Yawen Ding, Kai Li, Shiyuan Chang, Linsen Pei, Zhengwei Li, Zhenzhen Chen   +7 more
wiley   +1 more source

Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide

International Journal of Nanomedicine, 2012
Kwang-Ho Cha,1,3 Kyung-Jin Cho,3 Min-Soo Kim,4 Jeong-Soo Kim,3 Hee Jun Park,1,3 Junsung Park,1,3 Wonkyung Cho,1,3 Jeong-Sook Park,3 Sung-Joo Hwang1,21Yonsei Institute of Pharmaceutical Sciences, 2College of Pharmacy, Yonsei University, Incheon, Republic ...
Cha KH, Cho KJ, Kim MS, Kim JS, Park HJ, Park J, Cho W, Park JS, Hwang SJ   +8 more
doaj  

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Chronic kidney disease (CKD) is characterized by persistent inflammation that drives progressive renal injury and fibrosis. In this study, we demonstrate that disulfiram markedly attenuates kidney injury and fibrosis in adenine‐induced nephropathy by suppressing innate immune responses and reducing DNA damage and cellular senescence.
Saori Kin, Yuji Oe, Shun Ishigaki, Ichiro Fujio, Mariko Miyazaki, Tetsuhiro Tanaka   +5 more
wiley   +1 more source